What's in Polaryx Therapeutics, Inc.'s pipeline?

Polaryx Therapeutics, Inc. has 1 drugs in our index: 0 marketed, 0 filed, 1 in Phase 3, 0 in Phase 2, 0 in Phase 1.

Which companies overlap with Polaryx Therapeutics, Inc.'s portfolio?

Top competitors by shared drug class: Spectrum Pharmaceuticals, Inc.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/polaryx-therapeutics-inc.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-16 · How we verify

Polaryx Therapeutics, Inc. — Portfolio Competitive Intelligence Brief

Polaryx Therapeutics, Inc. pipeline: 0 marketed, 0 filed, 1 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

0 marketed 0 filed 1 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area	First approval
PLX-200	PLX-200	phase 3	PLK1 inhibitor	PLK1 (Polo-like kinase 1)	Oncology

Therapeutic area mix

Oncology · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

Spectrum Pharmaceuticals, Inc · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Polaryx Therapeutics, Inc.:

Cite this brief

Drug Landscape (2026). Polaryx Therapeutics, Inc. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/polaryx-therapeutics-inc. Accessed 2026-05-16.